目的 探讨西妥昔单抗联合5-氟尿嘧啶+顺铂(5-fluorouracil+cisplatin，FP)方案对中晚期食管癌患者肿瘤标志物及外周血磷脂酰肌醇-3 激酶信号通路关键蛋白(phosphatidylinositol3 kinase，PI3K)、蛋白激酶B信号通路关键蛋白(phosphorylated protein kinase B，pAKT)、微小核糖核酸-21(microribonucleic acid-21，miR-21)表达水平的影响。方法 将中晚期食管癌患者80例作为研究对象，用随机数字表法分为A组和B组，每组40例。A组给予FP方案治疗，B组在A组治疗的基础上加用西妥昔单抗。3周为1个周期，连续治疗4个周期。比较2组治疗后的临床疗效，治疗前、后的生存质量、功能状态、碱性成纤维细胞生长因子(basic fibroblast growth factor，bFGF)、可溶性E-钙黏蛋白(soluble E-cadherin，sE-Cad)、肿瘤标志物、PI3K、pAKT及miR-21和治疗期间的安全性。结果 治疗4个周期后，2组的总有效率比较差异无统计学意义(P>0。05)。治疗后，2组欧洲癌症研究组织生存质量测定表(European Organization for Research and Treatment of Cancer Quality of Life Questionnair，EORTC QLQ-C30)和卡氏功能状态(Karnofsky performance status，KPS)评分均升高，且B组高于A组;血清bFGF、sE-Cad、鳞状细胞癌抗原(squamous cell carcinoma antige，SCC)、癌胚抗原(carcinoembryonic antigen，CEA)、糖类抗原 125(carbohydrate antigen 125，CA125)、细胞角蛋白 19片段抗原(cytokeratin 19 fragment antigen21-1，CYFRA21-1)、外周血PI3K、pAKT和miR-21水平均降低，且B组低于A组(P<0。05)。2组治疗期间不良反应发生率比较差异无统计学意义(P<0。05)。结论 西妥昔单抗联合FP方案可有效降低中晚期食管癌患者肿瘤标志物水平，调节相关因子水平，改善患者血管内皮功能，进而提高患者生存质量及功能状态，临床疗效和安全性良好。
Efficacy of cetuximab combined with FP regimen in patients with middle and advanced esophageal cancer
Objective To explore the effects of cetuximab combined with 5-fluorouracil and cisplatin(FP)regimen on tumor markers and the expression levels of peripheral blood phosphatidylinositol-3 kinase signaling pathway key proteins(PI3K),protein kinase B signaling pathway key proteins(pAKT),and microribonucleic acid 21(miR-21)in patients with middle and advanced esophageal cancer.Methods 80 patients with middle and advanced esophageal cancer were selected as the study subjects,and they were divided into group A and group B by random number table method,40 cases in each group.The group A received FP regimen,while the group B received cetuximab on the basis of the group A.3 weeks was1 cycle,and continuous treatment lasted for 4 cycles.The clinical efficacy after treatmen,the quality of life,functional status,basic fibroblast growth factor(bFGF),soluble E-cadherin(sE-Cad),tumor markers,PI3K,pAKT,and miR-21 before and after treatment,and the safety during the treatment period were compared.Results After 4 cycles of treatment,there was no statistically significant difference in the total effective rate between the 2 groups(P>0.05).After treatment,the scores of European Organization for Research on Cancer Quality of Life(EORTC QLQ-C30)and cassiar functional status(KPS)of both groups increased,and the group B was higher than the group A.The levels of serum bFGF,sE-Cad,squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen(CYFRA21-1),peripheral blood PI3K,pAKT,and miR-21 decreased,and the group B was lower than the group A(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups during treatment(P>0.05).Conclusion The combination of cetuximab and FP regimen could effectively reduce the levels of tumor markers,regulate the levels of related factors,improve the endothelial function of patients with advanced esophageal cancer,and thereby improve their quality of life and functional status.The clinical efficacy and safety were satisfactory.
cetuximabFP scheme(5-fluorouracil+cisplatin)esophageal cancermiddle to late stagetumor markers
万方数据
维普
